Lysosomal Acid Lipase Is Required for Donor T Cells to Induce Graft-versus-Host Disease
Overview
Cell Biology
Molecular Biology
Authors
Affiliations
Graft-versus-host disease (GVHD) limits the success of allogeneic hematopoietic cell transplantation (allo-HCT). Lysosomal acid lipase (LAL) mediates the intrinsic lipolysis of cells to generate free fatty acids (FFAs), which play an essential role in the development, proliferation, and function of T cells. Here, we find that LAL is essential for donor T cells to induce GVHD in murine models of allo-HCT. Specifically, LAL is required for donor T cell survival, differentiation, and alloreactivity in GVHD target organs, but not in lymphoid organs. LAL induces the differentiation of donor T cells toward GVHD pathogenic Th1/Tc1 and Th17 while suppressing regulatory T cell generation. LAL T cells succumb to oxidative stress and become anergic in target organs. Pharmacologically targeting LAL effectively prevents GVHD development while preserving the GVL activity. Thus, the present study reveals the role of LAL in T cell alloresponse and pathogenicity and validates LAL as a target for controlling GVHD and tumor relapse after allo-HCT.
TBI/Cy followed by auto-HSCT is a good choice next to allo-HSCT for patients with T-LBL/ALL.
Mao J, Ge J, Ding S, Sun Z, Nan F, Yu H Sci Rep. 2024; 14(1):22356.
PMID: 39333693 PMC: 11437004. DOI: 10.1038/s41598-024-72897-9.
Lysosomal Acid Lipase Deficiency: Genetics, Screening, and Preclinical Study.
Mashima R, Takada S Int J Mol Sci. 2022; 23(24).
PMID: 36555187 PMC: 9779616. DOI: 10.3390/ijms232415549.
T-Cell Metabolism in Graft Host Disease.
Karl F, Hudecek M, Berberich-Siebelt F, Mackensen A, Mougiakakos D Front Immunol. 2021; 12:760008.
PMID: 34777373 PMC: 8586445. DOI: 10.3389/fimmu.2021.760008.
Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
Mohamed F, Thangavelu G, Rhee S, Sage P, OConnor R, Rathmell J Front Immunol. 2021; 12():757836.
PMID: 34712243 PMC: 8546182. DOI: 10.3389/fimmu.2021.757836.
Socie G, Kean L, Zeiser R, Blazar B J Clin Invest. 2021; 131(12).
PMID: 34101618 PMC: 8203454. DOI: 10.1172/JCI149296.